• LAST PRICE
    1.4500
  • TODAY'S CHANGE (%)
    Trending Down-0.0200 (-1.3605%)
  • Bid / Lots
    1.4100/ 1
  • Ask / Lots
    1.5700/ 2
  • Open / Previous Close
    1.4700 / 1.4700
  • Day Range
    Low 1.4100
    High 1.4900
  • 52 Week Range
    Low 1.3300
    High 10.2400
  • Volume
    222,701
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.47
TimeVolumeATNM
09:32 ET48431.46
09:35 ET3001.47
09:37 ET4351.44
09:44 ET1001.43
09:48 ET1001.43
09:50 ET13001.45
09:51 ET51791.43
09:53 ET3331.435
09:55 ET33521.46
09:57 ET11391.465
10:02 ET1001.465
10:06 ET9001.46
10:11 ET6001.46
10:13 ET1001.465
10:18 ET1001.465
10:20 ET11141.4654
10:24 ET11661.465
10:26 ET5001.47
10:27 ET2001.47
10:29 ET2001.465
10:33 ET2881.46
10:38 ET6001.46
10:45 ET4001.465
10:49 ET40091.45
10:58 ET14001.455
11:00 ET4161.455
11:02 ET1001.45
11:03 ET15001.455
11:07 ET4501.4536
11:09 ET11001.45
11:12 ET10261.45
11:16 ET3061.45
11:20 ET14441.455
11:34 ET1651.465
11:38 ET1001.46
11:39 ET83001.48
11:41 ET16001.48
11:43 ET19061.46
11:45 ET47001.46
11:48 ET108751.465
11:50 ET66051.46
11:52 ET130271.435
11:56 ET10001.44
11:57 ET1001.44
11:59 ET10001.445
12:01 ET4001.45
12:06 ET1001.45
12:08 ET2001.45
12:10 ET2001.45
12:12 ET3001.45
12:14 ET1001.45
12:15 ET6501.445
12:17 ET4001.45
12:19 ET2001.44
12:21 ET1001.45
12:24 ET6001.45
12:26 ET28001.45
12:28 ET1001.45
12:30 ET2001.45
12:32 ET1001.45
12:33 ET3001.45
12:35 ET21001.45
12:37 ET10001.445
12:39 ET3001.45
12:42 ET12001.44
12:44 ET3001.445
12:46 ET2691.445
12:48 ET29501.47
12:50 ET2651.461
12:51 ET15001.47
12:53 ET7201.465
12:55 ET2001.47
01:00 ET4661.4613
01:02 ET6001.46
01:06 ET3001.45
01:08 ET5681.45
01:09 ET2001.45
01:13 ET1001.45
01:24 ET1001.455
01:26 ET3881.45
01:29 ET1001.45
01:31 ET1241.45
01:33 ET1001.45
01:38 ET3201.45
01:40 ET1001.45
01:42 ET3361.45
01:44 ET103301.442
01:45 ET1001.44
01:47 ET13001.43
01:49 ET1001.43
01:51 ET3431.43
01:54 ET3061.4315
01:56 ET11001.43
01:58 ET2881.43
02:00 ET1001.43
02:03 ET32001.44
02:05 ET4001.435
02:07 ET2001.44
02:09 ET3981.435
02:12 ET30171.445
02:16 ET102001.445
02:18 ET1001.445
02:20 ET1201.4456
02:21 ET1001.4443
02:23 ET5001.4408
02:30 ET3001.44
02:32 ET2001.44
02:39 ET1001.44
02:41 ET3001.44
02:43 ET3001.445
02:45 ET5001.4419
02:48 ET1001.44
02:50 ET3371.4495
02:52 ET4831.44
02:56 ET4241.44
02:59 ET3001.44
03:01 ET2001.44
03:03 ET13791.44
03:06 ET1001.4389
03:08 ET8241.43
03:14 ET1001.435
03:19 ET5001.435
03:21 ET13001.4394
03:26 ET9001.43
03:28 ET32411.43
03:30 ET19161.415
03:32 ET2001.415
03:33 ET35001.4299
03:37 ET1001.435
03:39 ET13001.43
03:42 ET31451.425
03:44 ET42241.41
03:46 ET18381.42
03:48 ET35351.435
03:50 ET1001.435
03:51 ET10001.435
03:53 ET10001.435
03:55 ET1001.435
03:57 ET2001.435
04:00 ET151951.45
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesATNM
Actinium Pharmaceuticals Inc
45.2M
-1.0x
---
United StatesGANX
Gain Therapeutics Inc
44.7M
-1.5x
---
United StatesSER
Serina Therapeutics Inc
44.9M
-1.1x
---
United StatesOKYO
OKYO Pharma Ltd
35.5M
-1.5x
---
United StatesCALC
CalciMedica Inc
46.5M
-2.2x
---
United StatesIOBT
IO Biotech Inc
46.6M
-0.5x
---
As of 2024-11-23

Company Information

Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.

Contact Information

Headquarters
100 Park Ave., 23Rd FloorNEW YORK, NY, United States 10017
Phone
646-677-3870
Fax
845-818-3588

Executives

Chairman of the Board, Chief Executive Officer
Sandesh Seth
Chief Financial Officer
Steve O'Loughlin
Chief Business Officer
Lynn Bodarky
Director
June Almenoff
Independent Director
Jeffrey Chell

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$45.2M
Revenue (TTM)
$81.0K
Shares Outstanding
31.2M
Actinium Pharmaceuticals Inc does not pay a dividend.
Beta
0.09
EPS
$-1.40
Book Value
$1.32
P/E Ratio
-1.0x
Price/Sales (TTM)
558.4
Price/Cash Flow (TTM)
---
Operating Margin
-55,504.94%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.